Bolt Biotherapeutics, Inc. · Stock award · Employee Stock Option (Right to Buy)

What does this filing report?

An SEC Form 4 filing for Bolt Biotherapeutics, Inc. records a stock award involving Employee Stock Option (Right to Buy) on December 12, 2025. The reported quantity was 9,499. The filing date is December 16, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Derivative terms

Underlying security

Common Stock

Underlying quantity

9,499

Conversion / exercise price

5.44

Exercise date

Not reported

Expiration date

February 17, 2032

Filing footnotes & remarks

F1

The option is fully vested and exercisable.

F2

The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price.

F3

The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price.

F4

The reporting person agreed to cancellation of an option granted on April 4, 2018, in exchange for a new option having a lower exercise price.

F5

The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price.

F6

The reporting person agreed to cancellation of an option granted on November 13, 2019, in exchange for a new option having a lower exercise price.

F7

The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price.

F8

The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price.

F9

The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price.

F10

For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023.

F11

The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price.

F12

For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024.

F13

The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price.

F14

For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024.

F15

The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price.

F16

For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025.

F17

The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.